Yep. This article is typical of the reimbursement climate that is evolving. I recently had dinner with my old work associate who works for a large biotech in reimbursement. I brought up the analyst assumptions about $200-$300k per year for a chronic CF treatment. She is very familiar with CF and just scoffed at the notion that government and insurance agencies will ever pay that much. She pointed to the hesitancy that agencies have to pay $100 k for oncology treatments that often are not administered beyond the first year, with some exceptions like leukemia and small cell lung cancer. I honestly don't know where these analysts came up with their assumptions. I wonder if any of them took time to talk to independent reimbursement specialists, insurance providers and physicians. I think that they do a disservice to the public especially with these speculative plays.